- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03242590
Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). (DV)
October 11, 2019 updated by: Lipocine Inc.
Validation of Dosing Regimen of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men.
Multicenter, open-label, one treatment study evaluating the efficacy of LPCN 1021 in adult hypogonadal male subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
95
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Serum total T below 300 ng/dL based on 2 consecutive blood samples obtained between 6 and 10 AM, on two separate days at approximately the same time of day, following an appropriate washout of current androgen replacement therapy.
- Subjects should be diagnosed to be primary (congenital or acquired) or secondary hypogonadal (congenital or acquired).
- Naïve to androgen replacement or has discontinued current treatment and completed adequate washout of prior androgen therapy. Washout must be completed prior to collection of baseline serum T samples to determine study eligibility.
Exclusion Criteria:
- History of significant sensitivity or allergy to androgens, or product excipients.
- Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up.
- Abnormal prostate digital rectal examination (DRE) with palpable nodule(s).
- Subjects with symptoms of moderate to severe benign prostatic hyperplasia.
- Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis
- Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus antibodies (HIV Ab).
- History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.
- History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study drug administration.
- History of stroke or myocardial infarction within the past 5 years.
- History of or current or suspected prostate or breast cancer.
- History of untreated and severe obstructive sleep apnea.
- History of long QT syndrome (QTc > 450) or unexplained sudden death in a first degree relative (parent, sibling, or child).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Oral testosterone undecanoate, LPCN 1021
Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
|
Oral testosterone undecanoate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range
Time Frame: Following 24 days of treatment
|
The primary efficacy endpoint and analysis for this study was the percentage of LPCN 1021 treated subjects who had achieved a 24-hour average serum T concentration within the normal range of 300 to 1080 ng/dL at Visit 4, (Day 24 ± 4 days).
|
Following 24 days of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 1, 2016
Primary Completion (ACTUAL)
March 1, 2017
Study Completion (ACTUAL)
July 1, 2017
Study Registration Dates
First Submitted
August 3, 2017
First Submitted That Met QC Criteria
August 3, 2017
First Posted (ACTUAL)
August 8, 2017
Study Record Updates
Last Update Posted (ACTUAL)
October 23, 2019
Last Update Submitted That Met QC Criteria
October 11, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Gonadal Disorders
- Hypogonadism
- Eunuchism
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Androgens
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- LPCN 1021-16-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypogonadism, Male
-
Rigshospitalet, DenmarkTerminatedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleDenmark
-
Endo PharmaceuticalsCompletedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleUnited States
-
Clarus Therapeutics, Inc.CompletedMale Hypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Clarus Therapeutics, Inc.Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; PharmaN...CompletedMale HypogonadismUnited States, Germany
-
Clarus Therapeutics, Inc.inVentiv Health ClinicalCompleted
-
Lipocine Inc.PPD; Syneos HealthCompleted
-
University of Illinois at ChicagoNot yet recruitingMale Infertility | Male HypogonadismUnited States
-
Marius PharmaceuticalsSyneos HealthCompletedHypogonadism, MaleUnited States
-
Lund UniversityCompletedHypogonadism, Male
-
Ferring PharmaceuticalsCompletedAdult Male HypogonadismUnited States
Clinical Trials on LPCN 1021
-
BioLineRx, Ltd.TerminatedHealthy | VolunteersIsrael
-
Lipocine Inc.Completed
-
Lipocine Inc.CompletedHypogonadism, MaleUnited States
-
Lipocine Inc.PPD; Syneos HealthCompleted
-
Lipocine Inc.CompletedLiver Cirrhosis | SarcopeniaUnited States
-
Lipocine Inc.Active, not recruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Duramed ResearchCompletedContraceptionUnited States
-
Lipocine Inc.CompletedNonalcoholic Steatohepatitis (NASH)United States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedHealthyUnited States